Illinois Cannabis News
2 Illinois-specific articles plus federal updates affecting all states. 92 total articles.
Congressman Presses DOJ and DEA on Cannabis Rescheduling Timeline
US Congressman Steve Cohen (D-TN) sent a formal letter to Attorney General Bondi and DEA Administrator Cole demanding an update on cannabis rescheduling progress. The letter was sent 99 days after President Trump signed the executive order directing 'expeditious' completion of the Schedule III rulemaking process. Cohen, a long-time cannabis reform advocate, asked for a specific timeline and details on the procedural steps remaining before a final rule could be published. For cannabis operators watching the rescheduling timeline, Cohen's pressure reflects growing frustration from reform advocates that the process continues to drag despite the executive order, and reinforces that operators should not plan finances around any specific rescheduling date.
New Congressional Research Report on Cannabis Rescheduling Published
Congressional Research Service researchers released a new analysis noting that cannabis rescheduling to Schedule III would be a 'transitional' step requiring extensive follow-up reforms in banking, interstate commerce, and criminal justice. The report emphasized that rescheduling alone would not bring state-legal cannabis markets into full compliance with federal law, as Schedule III substances still require prescription-like protocols incompatible with adult-use retail models. The analysis is influential because congressional staff use CRS reports to shape policy proposals. For cannabis operators, the report validates industry arguments that rescheduling is necessary but insufficient, and that comprehensive federal legislation will still be needed to fully normalize state-legal markets.
Congressional Research Service Releases Comprehensive Cannabis Rescheduling Report
The Congressional Research Service published a comprehensive analysis concluding that cannabis rescheduling to Schedule III would eliminate Section 280E tax penalties but would not bring state-legal cannabis markets into full compliance with federal law. The report recommended follow-up legislation on banking, interstate commerce, and criminal justice.
Virginia Legislature Sends Cannabis Sales Legalization Bill to Governor
The Virginia General Assembly voted to adopt legislation legalizing adult-use cannabis dispensary sales, sending the bill to Governor Abigail Spanberger's desk. The bill establishes a January 1, 2027 launch date for retail sales and covers taxation, licensing priorities, social equity provisions, and regulatory responsibilities. Virginia has allowed personal possession and home cultivation since 2021, but previous administrations blocked a commercial retail framework. If signed, the bill will open one of the largest remaining untapped East Coast cannabis markets, with industry analysts projecting $2-3 billion in annual sales at maturity. For cannabis multistate operators with existing Virginia medical licenses, the legislation creates significant expansion opportunity.
Cannabis MSOs Owe $1.6 Billion in Unpaid 280E Taxes as IRS Fights Back
Major cannabis multistate operators collectively owe more than $1.6 billion in unpaid federal taxes under Section 280E, according to an analysis of public filings and IRS assessments. The IRS argued in court filings and tax notices that President Trump's December 2025 rescheduling executive order does not change existing tax obligations for prior years, and interest and penalties continue to accrue on unpaid balances. The $1.6 billion figure is concentrated among the top 10 MSOs and represents a significant portion of their balance sheet liabilities. For cannabis operators, the IRS's aggressive stance underscores that rescheduling alone will not retroactively forgive 280E liabilities, and operators should continue cash-reserving for tax payments.
Federal Government Warns About Cannabis and Hemp in Drug Tests
Federal agencies issued updated warnings about the impact of medical cannabis and hemp product use on standard workplace drug testing protocols. The guidance came amid growing tension between state-legal marijuana programs and federal drug testing requirements for federally-regulated positions including commercial drivers, federal employees, and safety-sensitive industries. The guidance clarified that state-legal use does not provide a defense against positive federal drug tests, even in states where adult-use cannabis is fully legal. For cannabis operators, the guidance highlights ongoing employment and insurance complications for workers who consume cannabis, and reinforces the need for operator-funded employee assistance programs and clear workplace policies on off-duty use.
Texas Voters Overwhelmingly Approve Cannabis Legalization Ballot Measure
Texas voters in the Democratic primary overwhelmingly approved a nonbinding cannabis legalization ballot question by a margin of roughly 80 percent to 20 percent. The measure asked whether the state should legalize cannabis for adults and automatically expunge prior marijuana-related criminal records. While the vote has no legal force to change Texas law, it provides a dramatic signal of primary voter sentiment in the country's second-most-populous state. The Texas Republican legislature has historically rejected all cannabis reform proposals, so near-term legalization remains unlikely. For cannabis operators, Texas represents one of the largest potential future markets but with no clear legislative path in the current political environment.
House Agriculture Committee Advances Farm Bill Without Hemp THC Ban Delay
The US House Committee on Agriculture voted 34-17 to approve the Farm, Food, and National Security Act of 2026 without provisions to delay the federal hemp THC ban. The bill tightens the legal definition of hemp to less than 0.4 percent total THC per container, effectively codifying the 2025 recriminalization law into the Farm Bill reauthorization. The committee rejected Republican amendments that would have pushed the effective date back two years. The vote sets up the broader House floor consideration of the Farm Bill and signals that the hemp ban is likely to take effect as scheduled in November 2026. For state-legal cannabis operators, this removes significant uncertainty about the timing of hemp competition disruption.
Supreme Court Justices Skeptical of Trump DOJ's Defense of Cannabis Gun Ban
During oral arguments in US v. Hemani, most US Supreme Court justices appeared skeptical of the Trump administration's defense of the federal firearms ban for marijuana users. Justices from across the ideological spectrum questioned whether the ban has sufficient historical grounding under the court's 2022 Bruen framework, and several suggested the government's rationale could justify unconstitutional restrictions on other law-abiding groups. Observers noted that Justices Barrett, Gorsuch, and Jackson appeared particularly skeptical during the exchange. For cannabis operators watching the case, the tenor of argument suggests a reasonable probability the court will strike down or narrow the ban in its forthcoming decision, removing a major federal criminal exposure for industry workers.
Hemp THC Ban Delay Hits Roadblock in Congress
The congressional effort to delay the federal hemp THC product ban hit a major procedural setback after two GOP-led amendments seeking a two-year delay were not approved. The House Agriculture Committee chairman determined the delay amendments were not germane to the underlying Farm Bill reauthorization, effectively blocking them from floor consideration. The ruling puts the November 2026 ban on track to take effect as scheduled unless separate standalone legislation advances. For state-legal cannabis operators, the setback is favorable: it accelerates the removal of unregulated hemp THC competition from the market, though hemp-diversified operators and hemp-only businesses face significant disruption to their product lines.
ACLU Previews Cannabis and Guns Arguments Ahead of Supreme Court Hearing
The American Civil Liberties Union previewed its arguments for the Supreme Court hearing in US v. Hemani in a published brief outlining its position that the federal marijuana gun ban violates the Second Amendment. In an unusual coalition, the National Rifle Association joined marijuana advocacy groups in urging justices to overturn the federal ban on gun ownership by cannabis users. The ACLU argued the ban lacks any historical analogue and improperly criminalizes state-legal behavior at the federal level. For cannabis operators and industry employees, a favorable ruling would remove one of the most concrete federal criminal risks associated with cannabis employment and allow workers to legally own firearms for personal or workplace security.
Congress Considers Hemp THC Product Ban Delay
Congressional lawmakers prepared to consider proposals to delay the federal ban on intoxicating hemp-derived THC products scheduled to take effect November 13, 2026. The ban would outlaw hemp products with more than 0.4 percent total THC per container, effectively eliminating most delta-8 THC, delta-10, THCP, and similar products from the legal hemp market. Industry stakeholders split on the delay: hemp businesses and several agricultural state delegations pushed for more time to transition, while state-legal cannabis operators and some public health groups opposed any delay. For cannabis operators, the debate determines how quickly unregulated hemp competition will be removed from the market.
Cannabis Legalization Appears on Texas Democratic Primary Ballot
Texas Democrats placed a nonbinding cannabis legalization question on the party's primary ballot, asking voters whether Texas should legalize cannabis for adults and automatically expunge prior records. Texas currently has no medical cannabis program beyond a restrictive low-THC epilepsy framework, and possession of even small amounts remains a criminal offense. The nonbinding measure has no legal force but is a signal to state legislators and national political observers about voter sentiment in the country's second most populous state. For cannabis operators, Texas remains a long-term opportunity with massive market potential but no clear legislative path in the immediate future.
DOJ Tells Supreme Court Gun Ban for Marijuana Users Must Be Upheld
The US Department of Justice argued before the Supreme Court in US v. Hemani that the federal gun ban for marijuana users must be upheld regardless of whether President Trump's rescheduling executive order is finalized. The argument came despite an earlier internal DOJ memo suggesting the ban might be unconstitutional under Bruen. DOJ attorneys maintained that the historical tradition of disarming those judged dangerous provides sufficient constitutional grounding for the current restriction. For cannabis operators, the DOJ's position signals that even under a pro-cannabis administration, the gun ban will not be voluntarily relaxed without court intervention or explicit legislative repeal, leaving employees and operators in legal gray zones on firearm possession.
FDA Faces Deadline for Cannabis Guidance on Hemp THC Serving Sizes
The FDA faced a statutory deadline to publish cannabinoid lists and issue guidance on 'container' definitions that will determine THC serving sizes under the hemp recriminalization law passed in late 2025. The underlying law requires that hemp products contain less than 0.4 percent total THC per container, but leaves the practical definition of 'container' ambiguous for beverages, gummies, tinctures, and other product formats. The FDA's guidance will determine whether many currently-legal hemp products remain on shelves after the November 2026 effective date. For cannabis operators, the guidance outcome directly affects hemp competition: narrow container definitions could eliminate most competing hemp products, while broad definitions could preserve significant gray-market competition.
Congressional Research Service Questions Constitutionality of Cannabis Tax Section 280E
A Congressional Research Service report found that whether Section 280E violates the Eighth Amendment's Excessive Fines Clause 'is a matter of debate' among legal scholars. The report noted that while the US Tax Court ruled in 2019 that 280E does not violate the Excessive Fines Clause, other courts have not had occasion to rule on the question, and the Harborside case left open several constitutional arguments that have not been fully litigated. The CRS analysis arrives amid multiple pending Tax Court challenges to 280E by cannabis operators. For cannabis businesses and their CPAs, the report is significant because it signals that congressional staff take the constitutional challenge seriously, which could influence any legislative response to rescheduling and 280E repeal efforts.
Cannabis M&A Activity Surges Following Trump Rescheduling Order
Cannabis merger and acquisition activity surged following President Trump's December 2025 rescheduling executive order, with multiple mid-sized deals announced in the first weeks of January 2026. Industry analysts cautioned that most of the activity reflected distressed consolidation rather than growth-stage dealmaking, as price compression and persistent oversupply continued to squeeze smaller operators. The increased deal flow was particularly pronounced in mature markets like Colorado, Oregon, and California, where wholesale prices have collapsed and smaller cultivators struggle to remain profitable. For independent operators, the M&A wave creates exit opportunities at lower valuations and accelerates the trend toward a smaller number of large vertically integrated operators controlling an increasing share of the legal market.
Virginia Cannabis Sales Legalization Bills Advance in Legislature
Virginia's House of Delegates and Senate both advanced competing bills to legalize adult-use cannabis retail sales under the state's new Democratic trifecta. Cannabis has been legal to possess and home-grow in Virginia since 2021, but previous administrations blocked the launch of a commercial retail market. The competing bills differ on tax rates, licensing priorities, and social equity provisions but both would establish the long-promised retail framework. For cannabis operators, a Virginia launch would open one of the largest remaining untapped East Coast markets, with estimated annual sales projections of $2-3 billion at maturity. Multistate operators with existing Virginia medical licenses would likely have a head start in any competitive licensing process.
Tennessee Lawmakers Introduce Bipartisan Medical Cannabis Bill
Tennessee Representatives and Senators introduced bipartisan legislation to decriminalize possession of medical cannabis for patients holding a physician's recommendation. Tennessee remains one of eight states without any medical cannabis program and has repeatedly rejected reform efforts over the past decade. The new bill stops short of authorizing a commercial dispensary framework but would eliminate criminal penalties for qualifying patients. The proposal reflects a slowly shifting political climate in deep-South states as rescheduling advances federally. For cannabis operators, any Tennessee reform remains a medium-term opportunity at best, but bipartisan introduction suggests the legislature is beginning to seriously consider the policy rather than dismissing it outright.
Big Banks Still Refusing Cannabis Industry Despite Trump Rescheduling Order
Major US banks continued refusing to service the estimated $32 billion legal cannabis industry despite President Trump's rescheduling executive order. JP Morgan Chase indicated it was still too early to reconsider its cannabis account restrictions, citing the ongoing administrative rescheduling process, unresolved FinCEN guidance, and the absence of SAFE Banking Act legislation. Other major financial institutions including Bank of America, Wells Fargo, and Citi maintained similar positions. The banks' caution reinforces that cannabis operators must continue relying on the small number of cannabis-friendly credit unions and specialized state-chartered banks for basic services. Rescheduling to Schedule III alone will not automatically resolve the banking problem, which requires separate federal action.
Bipartisan Senators File Bill to Delay Federal Hemp THC Ban
Senators Amy Klobuchar (D-MN), Rand Paul (R-KY), and Jeff Merkley (D-OR) introduced a bipartisan bill to delay enforcement of the federal hemp THC ban by two years. The underlying law, passed in late 2025, would recriminalize intoxicating hemp-derived products like delta-8 THC effective November 2026 by tightening hemp's legal THC definition to less than 0.4 percent per container. The senators argued that a two-year delay would give lawmakers time to develop a regulatory framework rather than abruptly disrupting the multi-billion dollar hemp beverage and edibles industry. For state-legal cannabis operators, the proposed delay is mixed: many welcomed the ban as removing unregulated competition, while hemp-diversified operators face significant disruption.
Vireo Growth Acquires Eaze for $47 Million
Cannabis multistate operator Vireo Growth agreed to acquire Eaze, once known as the Uber of Weed, in a $47 million all-stock transaction. The deal gives Vireo an additional 65 retail locations and Eaze's established delivery platform technology in California and several other Western states. Eaze had raised over $200 million at peak valuation before struggling through the 2022-2024 cannabis industry downturn. The acquisition is another example of distressed-asset consolidation reshaping the industry: tech-first cannabis businesses that burned through venture capital are being absorbed by vertically integrated operators with cash flow. For smaller cannabis brands, the deal signals that exits will increasingly happen through stock swaps at reduced valuations rather than cash buyouts.
U.S. Active Cannabis Business Licenses Decline 13% Over Two Years
The number of active cannabis business licenses in the US declined to 37,555 in the most recent quarter, down about 1 percent quarter-over-quarter and extending a downturn that began in late 2022. Over the past two years, total active cannabis licenses have dropped by roughly 13 percent nationally. The decline is concentrated in mature markets like Oregon, Oklahoma, and California where oversupply and price compression have forced small operators to surrender licenses. Newer markets including Missouri, New York, and Maryland are still adding licenses but at insufficient volume to offset losses elsewhere. For investors and ancillary service providers, the shrinking license count signals that the cannabis industry is consolidating rather than growing in raw operator count.
Federal Medical Cannabis Protections Approved in Congress
The US Senate voted to send President Trump legislation continuing federal protections for state-legal medical cannabis programs, extending the Rohrabacher-Blumenauer amendment that prevents the DOJ from using appropriated funds to prosecute compliant medical operators. The bill notably did not include a previously proposed rider that would have blocked Trump's cannabis rescheduling executive order. The continuation of medical program protections has been an annual must-pass item for the industry since 2014, though it offers no protection to adult-use operators. For cannabis businesses, the vote reinforces that federal enforcement risk for state-compliant medical operations remains low, but it does not extend to recreational programs or change Section 280E tax liability.
Trump Drug Czar Pushed to Back Full Cannabis Legalization
Cannabis reform advocates publicly pushed the Trump administration's drug czar to back full federal legalization rather than stopping at Schedule III reclassification. The lobbying effort came amid growing industry consensus that rescheduling alone would not solve interstate commerce barriers, persistent banking issues, or the fundamental conflict between state-legal markets and federal controlled substance status. Advocates argued that Schedule III still leaves cannabis as a controlled substance requiring prescription-like protocols that are incompatible with adult-use dispensary models. The push reflects operator frustration that Section 280E relief alone, while economically significant, would not resolve the structural legal contradictions state-legal cannabis businesses still face.
Trump Executive Order Directs Expedited Cannabis Rescheduling
President Trump signed an executive order directing the DEA and DOJ to expeditiously complete the cannabis rescheduling rulemaking process initiated in 2024. The order set a target completion timeline and represented the strongest White House push for cannabis policy reform in US history.
DEA Says Cannabis Rescheduling Process Remains Pending Despite Trump Executive Order
The DEA confirmed that the cannabis rescheduling appeal process remains administratively pending despite President Trump's December 2025 executive order directing expedited movement from Schedule I to Schedule III. The process had been effectively sidelined since January 2025 after the DEA's administrative law judge retired without a successor ruling on the interlocutory appeals. The DEA indicated no firm timeline for resolving the pending procedural motions, which must be cleared before any final scheduling rule can be published in the Federal Register. For cannabis operators, this means Section 280E federal tax exposure continues indefinitely, and any planned state-level decoupling moves or amended prior-year returns should not be timed to an assumed rescheduling date.
Supreme Court Schedules Oral Arguments in Cannabis and Gun Rights Case
The US Supreme Court agreed to hear US v. Hemani, a case challenging Section 922(g)(3) of the federal gun control law that bans marijuana users from possessing firearms. Several years of conflicting federal appeals court rulings created a circuit split on whether the ban violates the Second Amendment after the court's 2022 Bruen decision. The case has drawn unusual coalitions, with gun rights groups and cannabis advocacy organizations filing joint amicus briefs. A ruling striking down the ban would be a major practical win for cannabis operators, particularly cultivation and retail workers who currently face a federal felony if they own a firearm and are also registered medical patients or adult-use consumers.
Cannabis Edibles Giant Wyld Acquires Competitor Gron
Portland-based Wyld, the best-selling cannabis edibles brand in North America, announced the acquisition of fellow Oregon company Gron in an all-stock transaction. The deal combines two leaders in the roughly $4.8 billion US edibles category and gives Wyld additional footprint in chocolate and confection SKUs where Gron dominates. Post-acquisition Wyld operates in 16 states and roughly 7,500 retail locations, cementing its position as the largest multi-state edibles producer. The transaction reflects broader industry consolidation: with federal rescheduling looming, mid-sized brands are tucking into larger operators to secure shelf space and absorb 280E pressure before markets normalize.
Congress Removes Language Blocking Cannabis Rescheduling From Spending Bill
House and Senate Appropriations Committees released a bipartisan funding package that removed previously attempted language blocking the DOJ from using appropriated funds to reschedule cannabis. The rider had been included in earlier drafts by opponents seeking to freeze the administrative process, and its removal represents a significant retreat by cannabis reform opponents in Congress. The stripped rider clears one potential political obstacle to the DEA completing its Schedule III rulemaking. For cannabis operators watching the rescheduling timeline, the appropriations retreat suggests meaningful bipartisan accommodation even if formal legislation continues to stall, and reduces the risk of Congress halting the administrative process mid-stream.
Trump Signs Executive Order to Reclassify Cannabis to Schedule III
President Trump signed an executive order directing Attorney General Bondi to expeditiously finalize moving cannabis from Schedule I to Schedule III of the Controlled Substances Act. The order, signed on December 18, 2025, included a separate Medicare provision covering up to $500 annually for CBD products starting April 2026. The executive order was the most significant federal cannabis policy action in 50 years and represented a dramatic reversal from the DEA's earlier procedural stalling. The order did not itself reschedule cannabis but directed DOJ and DEA to complete the administrative rulemaking process already underway. For cannabis operators, the order signaled that federal tax relief from Section 280E could finally arrive within a reasonable timeline.
Federal Hemp THC Cap Bill Signed Restricting Intoxicating Hemp Products
Congress passed and the President signed legislation tightening the legal definition of hemp to require less than 0.4% total THC per container, effectively banning most intoxicating hemp-derived products like delta-8 THC. The law was signed in late 2025 with an effective date of November 2026, disrupting a multibillion-dollar hemp THC products industry.
Trump Signs Federal Ban on Intoxicating Hemp Products
President Trump signed legislation banning most intoxicating hemp-derived THC products, effectively recriminalizing the roughly $28 billion hemp THC market built since the 2018 Farm Bill. The ban limits hemp products to 0.4 milligrams total THC per container and takes effect November 13, 2026, giving hemp businesses approximately one year to transition or wind down. The law was driven by state cannabis regulators, public health groups, and state-legal cannabis operators who argued unregulated hemp THC products undermined tested, taxed cannabis markets. For state-legal cannabis operators, the ban removes a major source of unregulated competition, though hemp-diversified operators face significant disruption to their product lines and supply chains.
DEA Judge Retires, Leaving Cannabis Rescheduling in Limbo
DEA Administrative Law Judge John Mulrooney retired without ruling on the pending interlocutory appeals in the cannabis rescheduling proceeding, leaving the agency with no active administrative law judge to oversee the hearing. His departure shifted all pending procedural matters to newly confirmed DEA Administrator Terrance Cole, effectively pausing the rescheduling process indefinitely. The DEA had no immediate successor lined up and gave no timeline for resuming the administrative process. For cannabis operators, Mulrooney's exit was a significant practical setback: even with strong executive branch support for rescheduling, the process cannot advance without an administrative law judge to handle the procedural record.
Senate Confirms Terrance Cole as DEA Administrator
The US Senate confirmed Terrance Cole as DEA Administrator by a 50-47 vote, with Cole refusing during his confirmation hearing to commit to completing the Schedule III cannabis rulemaking. Cole later omitted cannabis rescheduling entirely from his stated strategic priorities for the agency, signaling a deprioritization of the process despite HHS recommendations and Biden administration pressure. The appointment came at a critical moment for the rescheduling timeline, just months before President Trump's December 2025 executive order demanded expedited completion. For cannabis operators watching federal timing, the confirmation added uncertainty to whether DEA leadership would actively advance the rescheduling process.
MedMen Enters Bankruptcy, Marking End of Once-Prominent Brand
MedMen Enterprises formally entered bankruptcy, with creditors reporting over $410 million in outstanding claims, ending the dramatic decline of what had once been called 'the Apple Store of weed' during its 2018-2019 peak. The company's liquidation was the largest and highest-profile cannabis bankruptcy in US history. At its peak, MedMen operated luxury dispensaries in prime retail locations across California, New York, and Nevada with celebrity branding. The collapse exemplified the industry's pattern of overspending, poor unit economics, and inability to absorb Section 280E tax pressure. For cannabis operators, the MedMen bankruptcy served as a case study in operational discipline failures and the risks of premium positioning without profitability.
Curaleaf Announces Major MSO Restructuring Amid Industry Consolidation
Curaleaf, one of the largest US multi-state cannabis operators, announced a major restructuring including layoffs and asset divestitures as the industry continued consolidating around a smaller number of profitable operators. The restructuring reflected continued pressure from 280E, capital scarcity, and price compression in mature markets.
Multiple States Move to Decouple State Tax Codes from IRC Section 280E
Cannabis operators in California, Colorado, Oregon, and several other states benefited from formal state tax code decoupling from Section 280E, allowing operating expense deductions on state returns even though federal 280E remained in effect. The decoupling movement provided meaningful tax relief while operators awaited federal rescheduling.
DEA Schedules Cannabis Rescheduling Hearing for January 2025
The DEA scheduled a public administrative hearing on the proposed cannabis rescheduling rule, signaling the agency's intent to thoroughly review opposition before finalizing any change. The hearing process meant rescheduling would extend well into 2025 and possibly beyond.
Leafly Delisted from Nasdaq Stock Exchange
Cannabis information and e-commerce platform Leafly was delisted from the Nasdaq stock exchange after failing to meet minimum income and market capitalization requirements. The company transitioned to over-the-counter trading at a fraction of its 2022 public debut valuation, marking another major casualty in the broader cannabis public company downturn. Leafly had raised over $200 million as a public company before ad revenue declined and its strain-review business model struggled against direct-to-consumer dispensary platforms. For the cannabis industry, the delisting reinforced that purely ancillary cannabis businesses face major headwinds in public markets and that exits will likely happen via restructuring rather than growth rounds.
Cannabis Lobbying Groups Merge to Form US Cannabis Roundtable
The National Cannabis Roundtable and the US Cannabis Council merged to form a unified federal lobbying organization, consolidating the two largest industry advocacy groups in Washington. The combined organization represents cannabis operators across 38 states and nearly 450,000 employees. The merger was driven by concerns that fragmented lobbying efforts had weakened the industry's voice on rescheduling, SAFE Banking, and 280E reform. The new group announced a coordinated strategy focused on completing rescheduling and advancing standalone banking legislation. For cannabis operators, the consolidation is a meaningful improvement in political coordination at a time when federal policy is finally moving.
Biden Commutes Nearly 2,500 Nonviolent Drug Sentences
In one of his final acts before leaving office, President Biden granted clemency to nearly 2,500 people imprisoned for nonviolent drug convictions. The commutations reduced sentences for individuals convicted of crimes that would receive lighter penalties under current federal law, including many cannabis offenses. Advocates welcomed the action but criticized the administration for leaving an estimated 1,500 people still incarcerated on federal cannabis charges despite years of reform promises. The clemency came without any structural policy change to federal cannabis prohibition. For the cannabis industry, the action reinforced the disconnect between executive sympathy for cannabis reform and the slow pace of actual legal change.
DEA Rescheduling Hearing Cancelled After Interlocutory Appeal
DEA Administrative Law Judge John Mulrooney granted an interlocutory appeal filed by cannabis rescheduling opponents, cancelling the public hearing that had been scheduled to debate moving cannabis from Schedule I to Schedule III. The cancellation effectively paused the entire rescheduling process, which had been working its way through the DEA since HHS recommended the move in August 2023. The hearing was expected to be the most significant public debate on federal cannabis policy in 50 years. For cannabis operators, the procedural delay extended Section 280E tax exposure and pushed any meaningful federal tax relief further into the future, reinforcing that rescheduling would not be a quick fix.
U.S. Regulated Cannabis Sales Top $31.4 Billion in 2024
Total US regulated cannabis sales reached approximately $31.4 billion in 2024, a 9.14 percent year-over-year increase driven primarily by new market launches and unit volume growth. Price compression remained a major challenge across mature markets, with average prices per eighth dropping nearly 40 percent since 2022 peaks in states like Colorado, Oregon, and California. The revenue growth came almost entirely from new market openings like Ohio, Maryland, and Missouri rather than mature market expansion. For cannabis operators, the numbers illustrated that the industry was growing in aggregate while individual operators in mature markets faced declining per-unit economics, reinforcing the importance of operating in newer, higher-margin markets.
SAFER Banking Act Fails to Advance in Lame-Duck Congress
The SAFER Banking Act failed to reach the US Senate floor during the lame-duck congressional session despite years of bipartisan support and consistent House approval. The bill had cleared the Senate Banking Committee with a 14-9 vote but could not overcome scheduling obstacles and Senate leadership prioritization of other end-of-year legislation. The failure extended the multi-year pattern of SAFER (previously SAFE) Banking passing the House multiple times without ever reaching a Senate floor vote. For cannabis operators, the lame-duck failure meant continued reliance on cannabis-friendly credit unions and specialized financial service providers rather than mainstream banking services, and extended the industry's cash-handling burden.
Historic DEA Rescheduling Hearing Opens in Arlington, Virginia
The first DEA administrative hearing on marijuana rescheduling convened in Arlington, Virginia on December 2, 2024, as a largely procedural session focused on establishing the hearing record and admitting evidence. Substantive testimony from pro- and anti-rescheduling witnesses was scheduled to begin January 21, 2025, though that schedule was later disrupted when the presiding administrative law judge retired. The hearing was the most significant federal cannabis policy proceeding in 50 years. For cannabis operators watching federal timelines, the procedural opening reinforced that even with strong executive branch support for rescheduling, the administrative process would extend well into 2025 and create ongoing uncertainty about Section 280E timing.
Nebraska Voters Approve Medical Cannabis Legalization
Nebraska voters approved two complementary medical cannabis ballot initiatives with 71 percent and 67 percent support respectively, establishing the framework for a state medical cannabis program in a traditionally conservative state. The initiatives authorized both possession by registered patients and the licensing of commercial producers and dispensaries. However, the results faced immediate legal challenges contesting the signature collection methods and validity of petition gatherers, threatening to invalidate the vote. The challenges were filed by opponents who had unsuccessfully tried to keep the measures off the ballot. For cannabis operators, Nebraska represented a potential new market pending resolution of the legal challenges.
Farm Bill Gets One-Year Extension, Leaving Hemp THC Loophole Intact
The US Congress extended the 2018 Farm Bill for an additional year rather than passing full reauthorization, leaving the hemp-derived THC loophole unchanged and legal. Despite multiple proposals to ban intoxicating hemp products like delta-8 THC, delta-10, and HHC during Farm Bill negotiations, no changes were made as congressional leaders prioritized avoiding controversial amendments. The extension kept the roughly $28 billion hemp THC market operating without federal restriction, frustrating state-legal cannabis operators who argued unregulated hemp competition undermined tested, taxed cannabis markets. For cannabis businesses, the extension effectively preserved the hemp THC market for another year until the 2025 federal ban finally took effect.
DEA Schedules Administrative Hearing, Delays Final Rule Past Election
The DEA announced a formal administrative hearing on cannabis rescheduling, adding an extra procedural step that pushed any final rule past the November 2024 presidential election. The decision significantly disappointed cannabis industry advocates who had hoped for a final rule before the election. The hearing would allow opponents including state attorneys general and drug policy groups to present testimony opposing rescheduling. Critics argued the hearing was an unnecessary delay tactic given the extensive public comment period already completed. For cannabis operators, the hearing schedule meant Section 280E exposure would continue throughout 2025 and potentially beyond, complicating tax planning and business forecasting.
DEA Cannabis Rescheduling Public Comment Period Closes With Record Submissions
The public comment period on the DEA's proposed cannabis rescheduling rule closed with over 43,000 comments submitted, the vast majority supporting the move to Schedule III. The comment volume exceeded almost any prior DEA rulemaking and signaled broad public engagement with the issue.
IRS Warns Cannabis Companies That 280E Tax Still Applies
The IRS issued a firm public warning that Section 280E continues to apply to cannabis businesses and that nothing has legally changed regarding marijuana's scheduling, directly rebutting the legal theories underlying multistate operator amended return refund claims. The agency announced specific procedural steps to reject amended returns seeking 280E tax refunds and signaled it would not settle cases or allow refund positions without litigation. The warning came amid growing MSO efforts to challenge 280E through the Tax Court. For cannabis CPAs and operators, the IRS statement made clear that even with rescheduling advancing, taxpayers should not plan on retroactive 280E relief or amended return refunds without prolonged and uncertain litigation.
Curaleaf Launches Hemp-Derived THC Product Line Nationwide
Cannabis multistate operator Curaleaf launched The Hemp Co., a direct-to-consumer hemp-derived THC product line available in 25 states where state-legal cannabis retail was not permitted. The move signaled a major pivot by licensed marijuana operators into the unregulated hemp THC market, which had grown to roughly $28 billion annually. The decision was controversial within the industry, with some operators criticizing Curaleaf for participating in a market that competed with state-legal cannabis while avoiding state taxes and testing requirements. For cannabis operators, Curaleaf's move highlighted the strategic dilemma of whether to join or oppose the hemp THC market, which was later resolved by the 2025 federal ban.
DEA Publishes Rescheduling Proposal, Opens 60-Day Public Comment Period
The DEA published its proposed cannabis rescheduling rule in the Federal Register on May 21, 2024, triggering a mandatory 60-day public comment period. The agency ultimately received more than 40,000 public comments on the proposal, exceeding almost any prior DEA rulemaking in comment volume and reflecting broad public engagement with cannabis policy. The vast majority of comments supported moving cannabis to Schedule III, though a significant opposition filed by state attorneys general and drug policy opponents created a procedural foundation for the later administrative hearing. For cannabis operators, the opening of the comment period formally started the countdown to rescheduling, though the actual timeline remained uncertain.
DEA Publishes Proposed Rule to Reschedule Cannabis to Schedule III
The DEA published a Notice of Proposed Rulemaking to reschedule cannabis from Schedule I to Schedule III, formally beginning the public comment process for the most significant federal cannabis policy change since the Controlled Substances Act of 1970. The proposed rule cited HHS findings that cannabis has accepted medical use and lower abuse potential than originally classified.
DEA Agrees to Reschedule Marijuana From Schedule I to Schedule III
The US Drug Enforcement Administration formally circulated a proposal to reclassify marijuana from Schedule I to Schedule III of the Controlled Substances Act, the most significant federal cannabis policy change in 50 years. The proposal, based on the HHS recommendation from August 2023, would officially recognize cannabis's medical value, allow cannabis businesses to deduct ordinary expenses under Section 280E, and remove certain research barriers that had limited cannabis studies for decades. The move did not legalize cannabis but would fundamentally change the tax economics of state-legal cannabis businesses. For cannabis operators, the DEA's agreement to advance rescheduling represented a long-awaited federal breakthrough after years of procedural stalling.
MedMen Files for Bankruptcy After Years of Mounting Losses
MedMen Enterprises filed for bankruptcy in California, ending a dramatic decline for what had once been called the 'Apple Store of weed' and a poster child for cannabis industry overspending. The collapse highlighted how 280E taxation, capital scarcity, and operational discipline failures had reshaped the industry.
Cannabis MSOs' Collective 280E Tax Liability Grows to $1.6 Billion
Five major cannabis multistate operators collectively accumulated approximately $1.6 billion in potential Section 280E tax exposure through amended return claims challenging the statute's application. The strategy was based on legal theories that 280E should not apply following rescheduling discussions or does not apply to certain operational structures. The IRS began aggressively pushing back, with the agency's tax attorneys warning publicly that past taxes paid under 280E are unlikely to be refunded and that the refund claims face significant legal obstacles. For cannabis CPAs and operators, the $1.6 billion figure illustrated both the enormous tax burden 280E had imposed and the uncertain outlook for recovering any of it through litigation.
Trulieve Surpasses $1 Billion Annual Revenue
Trulieve became one of the first US multi-state operators to surpass $1 billion in annual cannabis revenue, driven primarily by its dominant position in Florida's medical market. The milestone underscored the consolidation of US cannabis into a smaller number of large vertically integrated operators.
U.S. Cannabis Sales Projected to Reach $33.6 Billion in 2023
Combined US medical and recreational cannabis sales were projected to reach $33.6 billion for calendar year 2023, growing from approximately $30 billion in 2022. Growth was driven primarily by new adult-use market launches in Missouri, Maryland, and Connecticut, while mature markets in Colorado, Washington, and Oregon saw flat or declining revenues due to persistent price compression and oversupply. The overall growth masked significant regional divergence: newer markets were expanding rapidly while older markets were contracting. The total cannabis industry employment in the US was estimated at over 440,000 workers. For cannabis operators, the 2023 numbers illustrated the importance of market selection and timing in an industry where aggregate growth masked individual operator pain.
Cannabis Industry M&A Volume Hits $1.75 Billion With Smaller Deals
Cannabis industry mergers and acquisitions totaled approximately $1.75 billion in 2023, with combined equity and debt capital flows into the sector increasing 50 percent year-over-year despite depressed public company valuations. The average cannabis deal size dropped to $20.4 million, reflecting a pivot away from large transformational mergers toward smaller, strategic bolt-on transactions. The trend reflected both the collapse of mega-deal valuations and the availability of distressed assets as smaller operators exited the industry. Canadian and US multistate operators were the most active acquirers. For cannabis investors and operators, the 2023 M&A pattern confirmed that industry consolidation would continue but at lower prices and through strategic rather than transformational deals.
SAFER Banking Act Advances Through Senate Committee
The US Senate Banking Committee approved the SAFER Banking Act by a bipartisan 14-9 vote, marking the first time the upper chamber of Congress had advanced cannabis banking legislation out of committee. The bill would prohibit federal regulators from penalizing financial institutions that serve state-legal cannabis businesses, addressing the primary barrier to cannabis companies accessing mainstream banking services. The committee vote was a significant political milestone, though the bill ultimately did not reach the Senate floor during the 118th Congress. The SAFER Banking Act had been introduced in multiple forms over nearly a decade with consistent House passage but no Senate action. For cannabis operators, the committee vote offered hope even though the bill stalled.
HHS Recommends Rescheduling Marijuana to Schedule III
The US Department of Health and Human Services formally recommended that the DEA move marijuana from Schedule I to Schedule III of the Controlled Substances Act, marking the most consequential federal cannabis policy development in 50 years. HHS cited cannabis's accepted medical use and lower abuse potential compared to Schedule I substances as justification for the reclassification. The recommendation noted that over 30,000 healthcare practitioners across 43 jurisdictions authorize cannabis for more than 6 million registered patients under state medical programs. Schedule III reclassification would eliminate Section 280E tax exposure for state-legal cannabis businesses. For cannabis operators, the HHS recommendation was the federal breakthrough the industry had awaited for a decade.
HHS Officially Recommends Cannabis Reschedule to Schedule III
The Department of Health and Human Services formally recommended that the DEA reschedule cannabis from Schedule I to Schedule III of the Controlled Substances Act, marking the most consequential federal cannabis policy development in 50 years. Schedule III status would eliminate Section 280E tax penalties for state-legal operators.
Cresco Labs and Columbia Care Terminate $2 Billion Merger
The largest proposed cannabis merger in US history collapsed when Cresco Labs and Columbia Care mutually terminated their $2 billion all-stock deal. The companies had been unable to divest enough assets to satisfy state regulatory divestiture requirements by the agreement's deadline, particularly in New York, Illinois, and Ohio where the combined entity would have exceeded license caps. The termination was mutual and neither party paid a break-up fee. The failure reflected broader challenges facing cannabis M&A, including regulatory fragmentation across states, cash-strapped buyers, and declining valuations that made deal economics work less often. For cannabis operators, the Cresco-Columbia collapse signaled that large transformational cannabis mergers would remain difficult.
Mastercard Orders Banks to Block Cannabis Debit Transactions
Mastercard sent cease-and-desist letters to banks and payment processors, demanding they stop allowing marijuana purchases through the Mastercard debit card network. The move forced cannabis dispensaries to scramble for alternative payment solutions as the practice of processing cannabis purchases as generic retail debit transactions had been widespread. Many dispensaries had relied on what was known as 'cashless ATM' workarounds that ran purchases through the debit network. Mastercard's enforcement followed similar earlier actions by Visa. For cannabis operators, the crackdown reinforced that banking and payment normalization depend entirely on federal policy change or SAFER Banking legislation, and forced continued reliance on cash operations.
Delaware Legalizes Adult-Use Cannabis
Delaware became the 22nd US state to legalize recreational cannabis on April 23, 2023, when Governor John Carney allowed HB 1 and HB 2 to become law without his signature after previously vetoing similar legislation. The law permitted adults 21 and older to possess up to one ounce of flower and 12 grams of concentrates, and established a regulated commercial market. Delaware's legalization came despite Carney's personal opposition, reflecting a veto-proof legislative majority in the state. The commercial retail market was expected to launch in 2024 or 2025 following the licensing and regulatory framework development. For cannabis operators, Delaware opened another Northeast market to complement existing licensing in New Jersey and Maryland.
Delaware and Minnesota Legalize Recreational Cannabis
Delaware and Minnesota both legalized adult-use cannabis through legislative action in spring 2023, bringing the total number of US recreational states to 23. Minnesota Governor Tim Walz emphasized expungement and small business provisions in the state's licensing framework.
Hop Latent Viroid Spreads Across Cannabis Industry
Cannabis researchers found that hop latent viroid had infected approximately 90 percent of California cannabis grow facilities, causing an estimated $4 billion in annual industrywide losses across the US. The plant pathogen, first identified in hops, reduces THC and terpene levels while cutting yields by up to 42 percent in infected crops. Infection spreads asymptomatically through contaminated cutting tools, clones, and worker movement between facilities, making containment extremely difficult. The revelation prompted California cultivators to invest heavily in tissue culture, genetic testing, and biosecurity protocols. For cannabis operators, the viroid outbreak underscored the need for strict clone sourcing, regular plant testing, and facility biosecurity investments as core operational disciplines.
Canopy Growth Announces 60% Workforce Reduction
Canadian cannabis producer Canopy Growth, once the country's most valuable cannabis company at over $20 billion in market cap, announced plans to cut roughly 800 jobs, representing approximately 60 percent of its workforce. The company closed its iconic Smiths Falls headquarters in Ontario and shifted to a third-party sourcing model for most of its cultivation, projecting savings of C$140-160 million annually. The dramatic restructuring followed years of mounting losses after Canopy's Constellation Brands partnership failed to deliver expected growth. For the cannabis industry, Canopy's decline exemplified how premium valuations and heavy capital investment in early cannabis companies had given way to ruthless operational discipline and asset-light business models.
Cannabis Industry Layoffs Intensify in 2023 as Capital Dries Up
Major US and Canadian cannabis operators announced sweeping layoffs throughout early 2023 as falling wholesale prices, persistent 280E pressure, and frozen capital markets squeezed margins. Canopy Growth, Curaleaf, Cresco Labs, and others collectively laid off thousands of workers.
Maryland and Missouri Approve Recreational Cannabis on Election Day
Voters in Maryland and Missouri approved recreational cannabis ballot initiatives while Arkansas, North Dakota, and South Dakota rejected similar measures. The mixed results showed legalization faces real headwinds in conservative states despite strong national polling support.
President Biden Pardons Federal Simple Cannabis Possession Convictions
President Joe Biden issued a mass pardon for federal simple cannabis possession convictions, affecting an estimated 6,500 people, and directed HHS to begin a review of cannabis scheduling. The pardon was symbolic for state operators but the scheduling review eventually led to the Schedule III recommendation.
Major Multi-State Cannabis Vape Recall Over Pesticide Contamination
Multiple state cannabis regulators issued voluntary recalls of cannabis vape products tied to pesticide contamination above state action levels. The recalls underscored the importance of testing lab integrity and supply chain controls for finished cannabis products.
Illinois Social Equity Cannabis License Lottery Awards 185 Conditional Licenses
Illinois conducted a long-delayed social equity cannabis license lottery awarding 185 conditional adult-use dispensary licenses to applicants from communities disproportionately affected by the war on drugs. The lottery faced multiple legal challenges and exposed difficulties in implementing equity-focused licensing at scale.
New Mexico and Connecticut Legalize Recreational Cannabis
Governors in New Mexico and Connecticut signed adult-use cannabis legalization bills within months of each other, bringing the total number of US states with legal recreational cannabis to 18. Both states emphasized social equity provisions in their licensing frameworks.
Tilray and Aphria Complete Largest Cannabis Merger
Tilray and Aphria completed their merger in May 2021, creating what was at the time the world's largest cannabis company by revenue. The combined entity took the Tilray name and represented the consolidation trend reshaping global legal cannabis.
SAFE Banking Act Passes US House Multiple Times Without Senate Action
The Secure and Fair Enforcement (SAFE) Banking Act passed the US House of Representatives for the fifth time in early 2021, having been approved repeatedly without ever receiving a Senate vote. The recurring House passage reflected bipartisan support that consistently failed to overcome Senate procedural obstacles.
USDA Releases Final Hemp Production Rules Under 2018 Farm Bill
The US Department of Agriculture published final rules implementing the hemp production program authorized by the 2018 Farm Bill, setting THC testing requirements, sampling protocols, and disposal procedures for non-compliant crops. The rules established the regulatory framework for the federally legal hemp industry.
MORE Act Passes US House
The Marijuana Opportunity Reinvestment and Expungement (MORE) Act passed the US House 228-164, marking the first time a chamber of Congress had voted to remove cannabis entirely from the Controlled Substances Act. The bill did not advance in the Senate.
Arizona, Montana, New Jersey, and South Dakota Approve Recreational Cannabis
Voters in four states approved recreational cannabis legalization on Election Day 2020, with Mississippi simultaneously approving medical cannabis. South Dakota's recreational measure was later struck down by the state Supreme Court in 2021 as violating single-subject rules.
Cannabis Declared Essential Business During COVID-19 Lockdowns
Most US states with legal cannabis programs designated dispensaries as essential businesses during COVID-19 lockdowns, allowing them to remain open while non-essential retail shut down. The classification provided unprecedented legitimacy and triggered record sales months across multiple state markets.
SAFE Banking Act Passes US House for First Time
The Secure and Fair Enforcement (SAFE) Banking Act passed the US House of Representatives 321-103, marking the first time either chamber of Congress had approved cannabis-related legislation. The bill aimed to protect financial institutions serving state-legal cannabis businesses but stalled repeatedly in the Senate over subsequent years.
Vaping Illness Crisis Triggers Cannabis Industry Reckoning
An outbreak of EVALI (e-cigarette or vaping product use-associated lung injury) sickened thousands and was traced primarily to illicit-market THC vape cartridges containing vitamin E acetate. The crisis prompted state regulators to dramatically tighten cannabis vape testing requirements and triggered consumer flight back to flower.
Illinois Becomes First State to Legalize Recreational Cannabis Through Full Legislation
Governor JB Pritzker signed the Cannabis Regulation and Tax Act, making Illinois the first state to legalize adult-use cannabis sales entirely through legislative action with a comprehensive social equity component. The law authorized expungement of prior cannabis convictions for hundreds of thousands of residents.
2018 Farm Bill Legalizes Hemp and CBD Federally
President Trump signed the Agriculture Improvement Act of 2018, removing hemp (defined as cannabis with less than 0.3% delta-9 THC) from the Controlled Substances Act and creating the legal foundation for the nationwide CBD industry. The bill did not legalize marijuana or affect Section 280E for state-legal operators.
Missouri, Oklahoma, and Utah Approve Medical Cannabis on Election Day
Voters in Missouri, Oklahoma, and Utah approved medical cannabis ballot initiatives, expanding patient access across traditionally conservative states. Oklahoma's program would become one of the largest and most permissive medical markets in the US within 18 months of launch.
Canopy Growth and Constellation Brands Announce Major Investment
Constellation Brands announced a $4 billion investment in Canadian cannabis company Canopy Growth, the largest single investment in cannabis industry history at the time. The deal signaled mainstream beverage industry interest in cannabis but the partnership later struggled as Canopy faced significant losses.
Attorney General Sessions Rescinds Cole Memorandum
Attorney General Jeff Sessions formally rescinded the Cole Memorandum that had provided enforcement guidance protecting state-legal cannabis operators from federal prosecution since 2013. The move created widespread uncertainty but federal enforcement actions against compliant state operators did not materially increase.
Trump Administration Signals Mixed Messages on Cannabis Enforcement
Press Secretary Sean Spicer suggested federal cannabis enforcement could increase under the Trump administration, sending cannabis stocks tumbling and creating regulatory uncertainty for state-legal operators. Industry attention turned to whether AG Jeff Sessions would rescind the Obama-era Cole Memorandum.
Massachusetts, Nevada, and Maine Approve Recreational Cannabis on Election Day
Voters in Massachusetts, Nevada, and Maine all approved recreational cannabis legalization measures alongside California, more than doubling the population of US adults living in legal recreational states overnight. Florida, North Dakota, and Arkansas simultaneously approved medical cannabis programs.
DEA Denies Petition to Reschedule Cannabis from Schedule I
The DEA formally denied two petitions to reschedule cannabis out of Schedule I, concluding that cannabis has no currently accepted medical use and high abuse potential. The decision was widely criticized by reformers but kept Section 280E firmly in place for state-legal operators.
FinCEN Issues Cannabis Banking Guidance Allowing Limited Banking Services
The Financial Crimes Enforcement Network issued guidance allowing financial institutions to provide limited services to state-legal cannabis businesses without automatic federal money laundering enforcement. The guidance enabled a small number of cannabis-friendly credit unions and banks to emerge but most major financial institutions continued to refuse cannabis accounts.